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Abstract
 
Dysregulated T cell responses to enteric bacteria have been implicated as a common mecha-
nism underlying pathogenesis in rodent models of colitis. However, the bacterial species and T
cell specificities that induce disease have been poorly defined. We have developed a model sys-
tem in which target antigen, bacterial host, and corresponding T cell specificity are defined.
OVA-specific T cells from DO11.RAG-2
 
 
 
/
 
 
 
 TCR transgenic mice were transferred into
RAG-2
 
 
 
/
 
 
 
 recipients whose intestinal tracts were colonized with OVA-expressing or control
 
Escherichia coli
 
. Transfer of antigen-naive DO11.RAG-2
 
 
 
/
 
 
 
 T cells into recipients colonized
with OVA-
 
E. coli
 
 resulted in enhanced intestinal recruitment and cell cycling of OVA-specific
T cells; however, there was no development of disease. In contrast, transfer of polarized T
helper (Th) 1 and Th2 populations resulted in severe wasting and colitis in recipients colonized
with OVA-expressing but not control 
 
E. coli
 
. The histopathologic features of disease induced
 
by Th1 and Th2 transfers were distinct, but disease severity was comparable. Induction of disease
by both Th1 and Th2 transfers was dependent on bacterially associated OVA. These results es-
tablish that a single bacterially associated antigen can drive the progression of colitis mediated
by both Th1 and Th2 cells and provide a new model for understanding the immunoregulatory
interactions between T cells responsive to gut floral antigens.
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Introduction
 
Evidence from a growing number of rodent models of in-
flammatory bowel disease (IBD)
 
*
 
 supports a central role for
dysregulated CD4
 
 
 
 T cell responses to the enteric bacterial
flora as a common disease mechanism (1). Targeted dele-
tion or overexpression of a variety of genes important in
immune regulation or mucosal barrier function, and dis-
ruption of normal thymic development have produced
chronic inflammatory responses confined to the intestines
(2–8). In addition, transfers of normal T cell subsets defined
by differential expression of CD45RB into immunodefi-
cient mice demonstrate that different T cell populations can
promote or prevent colitis (9, 10). In the majority of these
models, the pattern of cytokine expression in inflammatory
lesions has implicated a Th1-dominated inflammatory dis-
ease, and neutralization of IL-12, IFN-
 
 
 
, or TNF-
 
 
 
 has
been therapeutic (11–14). In a few models, a Th2 pattern
of cytokine expression has been observed (15, 16), and
neutralization of IL-4 or targeted deletion of IL-4–pro-
ducing cells was protective (16, 17). In human IBD, there
is evidence that Crohn’s disease is associated with a Th1
pattern of inflammation (18, 19). Elevation of some Th2
cytokines has been detected in ulcerative colitis (18), but
whether the disease is associated with Th2 dominant re-
sponses is unclear.
Although many of the animal models of IBD have sys-
temic disruptions of T cell regulatory mechanisms, inflam-
matory disease localizes primarily or exclusively to the large
intestine. Because the cecum and colon of the large intes-
tine contain the bulk of the enteric flora, it has been pro-
posed that dysregulated T cell populations in these models
are reactive to components of the normal intestinal flora
(20, 21). This is supported by the abrogation of colitis devel-
 
opment in germ-free HLA-B27 transgenic rats and IL-2
 
 
 
/
 
 
 
and IL-10
 
 
 
/
 
 
 
 mice, and the rapid development of colitis
upon reconstitution of the enteric flora (4, 22, 23). It has
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Both Th1 and Th2 Are Pathogenic in Colitis
 
also been shown that T cells developing in the abnormal
thymic microenvironment of Tg
 
 
 
26 mice do not induce
colitis in the absence of normal bacterial antigen (24). Sim-
ilarly, depletion of the enteric flora by broad-spectrum an-
tibiotic treatment has ameliorated disease in several murine
models of colitis. Antibiotic manipulations in the HLA-
B27 transgenic rats and DSS-treated mice have also sug-
gested that complex interactions of aerobic and anaerobic
commensal bacteria provide the stimulus for chronic in-
flammation in these models (25). More direct evidence im-
plicating enteric bacterial antigens is found in data from
studies in the spontaneously colitic C3H/HejBir mouse
strain (26). CD4 T cells isolated from these mice are reac-
tive to a mixture of cecal bacterial antigens and induce coli-
tis upon transfer to immunodeficient hosts (27). These
studies strongly suggest that the enteric bacterial flora pro-
vides the stimulus for development of colitis in the setting
of altered immunoregulatory mechanisms.
The mechanism by which the bacterial flora stimulates
colitis in susceptible models is unknown and is likely to be
multifactorial. Bacterial components may act as immune
adjuvants or may provide bacterial superantigens that non-
specifically activate an adaptive immune response. Alterna-
tively, proinflammatory bacterial wall components may
initiate or direct a pathologic inflammatory response inde-
pendent of specific immunity. However, the fact that T
cell regulatory dysfunction is involved in experimental
colitis indicates that specific recognition of bacterial anti-
gens is central to disease pathogenesis. An intriguing find-
ing in this regard has been the relative selectivity of im-
mune responses to a limited number of bacterial species in
mouse and rat colitis models (22, 28, 29). Nevertheless, de-
tails regarding the types of enteric bacteria that are respon-
sible for initiating and perpetuating a pathogenic T cell re-
sponse and the specific bacterial antigens recognized remain
poorly defined.
A significant impediment to advances in our understand-
ing of homeostatic and pathogenic intestinal T cell re-
sponses is the lack of identified target antigens and their
corresponding T cell receptor specificities. In none of the
existing models are specific bacterial species and their anti-
gens or the responsive T cell specificities defined. The goal
of the current studies was the development of a model sys-
tem for characterization of T cell responses to bacterially
associated enteric antigens in which the target antigen, bac-
terial host, TCR specificity, and T cell developmental stage
are each defined. To this end, we have adapted the well-
characterized DO11.10 
 
  
 
 TCR transgenic model to ex-
amine the inductive and regulatory effects stimulated by
free or bacterially associated cognate antigen, OVA. Adop-
tive transfers of antigen-naive or polarized Th1 or Th2 cells
derived from recombination activating gene (RAG)-2–
deficient DO11.10 mice were made into congenic RAG-2–
deficient recipients colonized with 
 
E. coli
 
 engineered to ex-
press OVA or a control antigen. Using this system, we have
observed for the first time that precommitted Th1 and Th2
cells reactive to a single bacterially associated antigen can be
colitogenic, whereas naive cells are not.
 
Materials and Methods
 
Mice.
 
Specific pathogen-free BALB/cBJ, DO11.10 (30),
BALB.RAG-2
 
 
 
/
 
 
 
, and DO11.10 TCR transgenic mice crossed
with RAG-2
 
 
 
/
 
 
 
 mice (DO11.RAG-2
 
 
 
/
 
 
 
) were bred and/or
maintained in the Genetically Engineered Mouse facility at Uni-
versity of Alabama at Birmingham. DO11.10 and RAG-2
 
 
 
/
 
 
 
mice had been backcrossed onto the BALB/c background for at
least 10 generations before intercrosses to generate mice homozy-
gous for the RAG-2 targeted mutation and hemizygous for the
DO11.10 transgene (DO11.RAG-2
 
 
 
/
 
 
 
). Male and female
DO11.RAG-2
 
 
 
/
 
 
 
 mice were used as donors for adoptive transfer
studies; female BALB.RAG-2
 
 
 
/
 
 
 
 mice were used as recipients.
All experimental mice were 6–10 wk of age.
 
Generation of OVA-producing Escherichia coli. Escherichia coli
 
was chosen as the bacterial host for these studies because of the
relative ease with which it is genetically modified and its demon-
strated role as an “immunodominant” organism in spontaneously
colitic mice (28). The full coding sequence of OVA or TET-C
(C fragment of tetanus toxoid, as a control) was expressed in 
 
E.
coli
 
 strain DH5
 
 
 
 under the control of an inducible bacterial pro-
moter, 
 
nir
 
15 (31). The 
 
nir
 
15 promoter is an improved expression
variant of the 
 
nirB
 
 promoter of the nitrite reductase gene of 
 
E.
coli
 
 that is strongly induced by environmental nitrites or low ox-
ygen tension (32). This promoter has been used to direct stable
in vivo expression of heterologous antigens in vaccine strains of
 
Salmonella
 
 (31, 33). The plasmid pTET
 
nir
 
15 (reference 31; re-
ferred to henceforth as pnir15.TET) expresses the C fragment of
tetanus toxoid and was provided by Jerry McGhee and James
Lillard, University of Alabama at Birmingham. To produce an
OVA-expressing variant, pnir15.OVA, the TET coding se-
quence was excised by BglII/BamH1 digestion and replaced
with a pcr-generated fragment that included an idealized Shine-
Dalgarno sequence upstream of the entire OVA coding sequence
(forward primer: 5
 
 
 
 CTTATAGATCTTAATCATCCACAG-
GAGATATTATTATGAAAAACATCGGCGCAGCAAGCA-
TGGAA; reverse primer: 5
 
 
 
 GCTAGCGGATCCTTAAGGG-
GAAACACATCTGCC). The plasmid VR1020/OVA was used
as a template for amplifying the OVA coding sequence (pro-
vided by William O. Rogers, Naval Medical Research Center,
Bethesda, MD). DH5
 
 
 
 
 
E. coli
 
 were transformed by each plas-
mid (pnir15.OVA or pnir15.TET) by electroporation and se-
lected for ampicillin resistance. Clones containing pnir15.OVA
were isolated and sequenced to prove authenticity of the OVA
coding sequence. Expression of OVA in 
 
E.
 
 
 
coli
 
 was confirmed
by Western blot analysis after overnight culture in media con-
taining ampicillin, without shaking in tightly capped tubes at
37
 
 
 
C for anaerobic induction of 
 
nir
 
15 promoter. Bacteria were
lysed in 2
 
 
 
 sample buffer (6% TRIS-Cl, pH 6.8, 20% glycerol,
4% SDS, 2% 2-ME), and heat denatured at 100
 
 
 
C for 5 min.
Cell lysates (10
 
5
 
 cell equivalents) and purified OVA (positive
control) were resolved on a 10% SDS polyacrylamide gel and
transferred to nylon membranes (Nytran Plus; Schleicher &
Schuell). Membranes were incubated at room temperature with
1% blocking reagent (Boehringer Mannheim) for 1 h, a 1:500
dilution of murine anti-OVA mAb, OVA-3 (IgG2
 
 
 
; Brook-
wood Biomedical) for 2 h, and were detected with POD-con-
jugated anti–mouse IgG/anti–rabbit IgG (40 mU/ml; Boeh-
ringer Mannheim) using the chemiluminescent substrate
luminol (Boehringer Mannheim).
 
Cell Purification and Flow Cytometry.
 
CD4
 
 
 
 T cells were iso-
lated from pooled spleens and peripheral lymph nodes of
DO11.10 or DO11.RAG-2
 
 
 
/
 
 
 
 mice using mouse CD4 (L3T4)
Dynabeads
 
® 
 
followed by CD4 DETACHaBEAD
 
®
 
 per the manu- 
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facturer’s protocol (Dynal Biotech). The resulting CD4
 
 
 
 en-
riched cells were stained with FITC-conjugated KJ1–26 (anti-
DO11.10 TCR, reference 34) and PE-conjugated anti-CD4 and
analyzed by flow cytometry to determine purity of the popula-
tion. 10,000 total events were acquired on a Becton Dickinson
FACScan™, gating on cells with forward and side scatter proper-
ties of lymphocytes, and were analyzed using CELLQuest™ soft-
ware. Isolations routinely resulted in 
 
 
 
92% purity of CD4
 
 
 
 cells
(DO11.10 donors) or CD4
 
 
 
KJ1–26
 
 
 
 cells (DO11.RAG-2
 
 
 
/
 
 
 
).
 
In Vitro and In Vivo Analyses of DO11.10 T Cell Response to
OVA-expressing E. coli.
 
For in vitro studies, splenic adherent
cells isolated from BALB/c mice were pulsed for 18 h with noth-
ing, 100 
 
 
 
g/ml whole OVA, or the indicated number of genta-
mycin-killed, anaerobically induced pnir15.TET or pnir15.OVA
 
E. coli
 
. Gentamycin killing was done by incubating bacteria with
100 
 
 
 
g/ml gentamycin for 30 min. Pulsed splenic adherent cells
were then irradiated (2,500 rads) before culture with CD4
 
 
 
 T
cells isolated from DO11.10 mice. Day 3 proliferative responses
were determined by 
 
3
 
[H]-TdR incorporation as described previ-
ously (35). For in vivo studies, 5 
 
 
 
 10
 
6
 
 CD4
 
 
 
KJ1–26
 
 
 
 T cells
isolated from DO11.10 mice were transferred into BALB/c mice
by tail vein injection. 1 d after the transfer, 10
 
6
 
 bacteria (
 
E. coli
 
-
OVA or -TET) were injected IV and mice were killed at days 1,
3, 5, 7, and 9. Cells from spleen and lymph nodes were pooled
and analyzed by FACS
 
®
 
 for expression of CD4 and DO11.10
TCR and the total number of CD4
 
 
 
KJ1–26
 
 
 
 cells were calcu-
lated as described previously (36).
 
Generation and Characterization of OVA-specific Th1 and Th2
Cells.
 
Th1 and Th2 cells were generated in vitro from antigen-
naive CD4
 
 
 
 T cells as described previously (37). Briefly, purified
CD4
 
 
 
 T cells isolated from pooled spleens and peripheral lymph
nodes of DO11.RAG-2
 
 
 
/
 
 
 
 were cultured at a ratio of 1:10 with
irradiated BALB/c splenocytes and 5 
 
 
 
g/ml OVA peptide 323–
339. The addition of 50 U/ml IL-12 (R&D Systems) and 10 
 
 
 
g/
ml anti–IL-4 (11B11; reference 38) was used to generate Th1
cells, while 1,000 U/ml IL-4 (R&D Systems) and 10
 
  
 
g/ml anti–
IL-12 (C17.8, reference 39) was used to generate Th2 cells (40).
Recovered cells were washed and transferred on day 7 at 10
 
6
 
cells/RAG-2
 
 
 
/
 
 
 
 recipient mouse. A separate aliquot of 5 
 
 
 
 10
 
6
 
cells was restimulated for 6 h with PMA (50 ng/ml) and ionomy-
cin (750 ng/ml; Sigma-Aldrich) for analysis of cytokine mRNA
expression by ribonuclease protection assay. Ribonuclease pro-
tection assays were performed with 1 
 
 
 
g of RNA using the tem-
plate set mCK-1 (RiboQuant kit; BD PharMingen).
 
Reconstitution of RAG2
 
 
 
/
 
 
 
 Mice with CD4 Subsets, Colonization
with Bacteria, and Monitoring for Development of Colitis.
 
Bacterial
colonization was performed by gastric gavage of pnir15.OVA-
 
E.
coli
 
 or pnir15.TET-
 
E. coli
 
 (control) to RAG-2
 
 
 
/
 
 
 
 mice one day
before CD4 T cell transfer. Bacteria were grown in LB medium
overnight at 37
 
 
 
C under anaerobic conditions and 10
 
10
 
 CFU in
100 
 
 
 
l PBS were administered orally using a straight gavage nee-
dle. Colonization was assessed by plating stool suspensions on LB
plates containing ampicillin and was maintained at 
 
 
 
10
 
8
 
 CFU/g
of stool by biweekly gavage. 10
 
6
 
 naive, Th1, or Th2 DO11.10
CD4
 
 
 
 T cells were transferred by tail vein injections into RAG-
2
 
 
 
/
 
 
 
 mice a day after the first gavage. Mice were weighed weekly
and monitored for appearance, and signs of loose stool and diar-
rhea. 0.8 mg/ml bromodeoxyuridine (BrdU) was added to the
drinking water of all groups for 9 d before killing and intestinal
tissues were evaluated histologically.
 
Histopathologic Assessment and Disease Scoring.
 
At necropsy,
the small intestine, cecum, and colon were separated and Swiss
rolls of each prepared. Tissues were fixed in 10% buffered forma-
 
lin and paraffin 5-
 
 m embedded sections were stained with
H&E. Additional sections were stained for identification of poly-
morphonuclear cells (Leder stain), eosinophils (cyanide-resistant
eosinophil peroxidase stain; reference 41), T cells (anti-CD3),
and/or BrdU as indicated. An immunohistochemical method for
coidentification of CD3 cells and BrdU-labeled cells was devel-
oped for these studies and will be described in detail elsewhere
(unpublished data). Briefly, 5- m sections were digested with
pepsin, blocked with normal goat serum, and sequentially incu-
bated with polyclonal rabbit anti–human CD3 antibody (0.5  g/
ml, 1:100 dilution, 30 min; Dako), biotinylated anti–rabbit IgG
(H L) antibody (1.5  g/ml: 1:100 dilution, 30 min), and 0.3%
hydrogen peroxide (10 min). Bound antibody was then detected
with a preformed avidin and biotinylated horseradish peroxidase
macromolecular complex (ABC; Vectastain Elite ABC kit; Vec-
tor Laboratories) and diaminobenzadine substrate was used for
development (Vector Laboratories). After development of anti-
CD3 staining, sections were rinsed with PBS followed by incuba-
tion in denaturing solution for 20 min (BrdU Staining kit;
Zymed Laboratories). Slides were then sequentially incubated
with biotinylated mouse anti-BrdU antibody for 30 min, alkaline
phosphatase labeled streptavidin for 20 min, and detected with
Fast Red TR chromogen for 30 min (BrdU Staining kit; Zymed
Laboratories). Slides were counterstained with hematoxylin and
coverslips mounted with crystal mount (Biomeda). All incuba-
tions were performed at room temperature and each step was fol-
lowed by a rinse with PBS. Sections processed without primary
antibody served as negative controls.
Histological scoring was performed using a modification of the
scoring system reported previously by Sundberg et al. (42), and
was performed independently by two pathologists (A.S. Lazenby
and C.T. Weaver). Briefly, each section was scored for lesions
based on four criteria: severity of inflammation, hyperplasia of
mucosal epithelium, mucosal ulceration, and extent of involve-
ment. Severity of inflammation and hyperplasia were graded on a
score of 0–3, 0 being normal and 3 being severe. The extent of
disease involvement was determined for each and defined as: 0,
normal; 1, 1–33%; 2, 34–66%; and 3, 67–100%. The percent area
of involvement was determined separately for cecum, proximal
colon, middle colon, and distal colon/rectum. The average area
of involvement for the colon was calculated as the sum of the
three colonic segments divided by three and was used for calcula-
tion of the total colon score. The total score was assessed sepa-
rately for the cecum and colon by adding the scores of severity,
hyperplasia, area of involvement, and ulceration. The thickness of
mucosal hyperplasia was directly measured in the areas of most
severe disease using an ocular grid, but was not included as a
component of the disease score. All cell counts were performed at
original magnifications: 200  or 400  by point counting using
an ocular grid (36); a minimum of 1,000 total cells was counted
for each determination.
Isolation and Cytokine Phenotyping of Intestinal Lamina Propria T
Cells. Colon and small intestine were washed thoroughly with
PBS to remove debris, opened longitudinally, and then cut into
0.5 cm pieces. The epithelium was removed by incubation with
2 mM DTT (Sigma-Aldrich) and 1 mM EDTA (Sigma-Aldrich)
in RPMI 1640 medium supplemented with 2% FCS at 37 C for
30 min with gentle shaking. Tissue was collected, further cut
into smaller pieces, and digested with 0.3 mg/ml collagenase
type IV (Sigma-Aldrich) at 37 C for 90 min. Lamina propria
(LP) cells were harvested by discontinuous 40/70 percoll gradi-
ent (BD PharMingen). CD4  T cells were then purified from LP
mononuclear cells by positive selection using mouse CD4 Dyna-74 Both Th1 and Th2 Are Pathogenic in Colitis
beads® and mouse CD4 DETACHaBEAD® as described previ-
ously (Dynal). Recovered cells were cultured in 96-well plates
(Nunc) that were precoated with anti-CD3 mAb (145–2C11;
reference 43; 10  g/ml) in 100  l PBS at 37 C for 4 h and
washed with PBS three times to remove unbound Ab. LP CD4 
T cells (5   105 cells per milliliter) were incubated in the pres-
ence of coated anti-CD3 and soluble anti-CD28 (37.51, refer-
ence 44; final concentration, 1  g/ml) at 37 C. After 72 h of
culture, supernatants were harvested and assayed for IFN- ,
IL-4, and IL-10 by capture ELISA using commercially available
ELISA kits (R&D Systems).
Statistical Analyses. Parametric data were analyzed by Student’s
t test. Nonparametric data were analyzed by the Mann-Whitney
test. P values   0.05 were considered significant.
Results
Generation and Characterization of OVA-producing E.
coli. To generate bacteria that express the antigen recog-
nized by the DO11.10 TCR, a plasmid encoding the full-
length OVA cDNA (pnir15.OVA) was introduced into
DH5  E. coli (Fig. 1 A). E. coli was chosen as the bacterial
host because it is a normal commensal and because it is an
immune stimulatory organism in spontaneously colitic
mice (28). Western blot analyses of lysates of DH5  E. coli
transformed with the pnir15.OVA plasmid indicate that
this construct directs excellent cytosolic expression of OVA
protein under anaerobic conditions (Fig. 1 B). E. coli trans-
formed with a plasmid in which the coding sequence of
OVA was replaced with that of the C fragment of tetanus
toxoid (pnir15.TET-E. coli) served as a negative control.
Based on densitometric comparisons between immunoblots
performed with bacterial lysates of pnir15.OVA-E. coli and
purified OVA, the anaerobically induced plasmid expressed
 1  g OVA per 106 bacteria under in vitro conditions.
The immunogenicity of pnir15.OVA-E. coli was deter-
mined in vitro by T cell proliferation assays (Fig. 1 C).
Splenic adherent cells pulsed with anaerobically induced,
gentamycin-killed pnir15.OVA-E. coli–stimulated prolifer-
ation of naive DO11.10 T cells, whereas splenic adherent
cells pulsed with pnir15.TET-E. coli did not. The dose of
bacteria that stimulated a maximal response (107 organisms)
expressed  10  g OVA; the dose of free OVA that was
required for a maximal response was 100  g/ml. Thus, in-
duced pnir15.OVA-E. coli are a potent immunogen for
stimulation of DO11.10 cells in vitro.
The immunogenicity of live pnir15.OVA-E. coli was as-
sessed in vivo using a DO11.10 adoptive transfer system
(45). Normal BALB/c mice that received transfers of 5  
Figure 1. Inducible expression of immunogenic OVA by pnir15.OVA-E. coli. (A) Schematic of the pnir15.OVA plasmid. Restriction enzyme sites are:
Bgl, Bgl II; RV, Eco RV; B, Bam H1. The ampicillin resistance gene (Ampr) and origin of replication (pBR322ORI) are indicated. (B) Western blot anal-
ysis of DH5  E. coli transformed with pnir15.OVA or a control plasmid that codes for expression of the C fragment of tetanus toxoid (pnir15.TET). Cy-
tosolic fractions of lysates of bacteria cultured for 12 h under aerobic ( ; noninduced) or anaerobic ( ; induced) conditions were prepared and analyzed by
Western blotting (see Materials and Methods). The indicated lanes were loaded with 6   105 bacterial equivalents or 500 ng purified native OVA. The anti-
body used for detection was a murine IgG2b monoclonal (OVA-3) that is specific for OVA. Note that the bacterially expressed OVA runs at a lower MW
than native OVA due to absent glycosylation. (C) Splenic adherent cells isolated from BALB/c mice were pulsed for 18 h with the indicated number of
gentamycin-killed, anaerobically induced pnir15.TET-E. coli (white circles) or pnir15.OVA-E. coli (black circles) then irradiated (2,500 rads) before culture
with CD4  T cells isolated for DO11.10 mice (left). The response of the same cells to APCs pulsed with nothing or an optimal dose of native OVA (100
 g/ml) is shown for comparison (right). Data are the mean   SD of day 3 proliferative responses determined by 3[H]-TdR incorporation.75 Iqbal et al.
106 DO11.10 CD4  T cells (DO11.10/BALB mice) were
innoculated intravenously with 106 pnir15.OVA-E. coli or
pnir15.TET-E. coli, and expansion of the clonotypic T cell
population in the spleens of recipient mice was monitored
by flow cytometric analysis (Fig. 2). In agreement with a
previous study by Chen et al. (46), intravenous administra-
tion of the OVA-producing E. coli stimulated a robust
clonal expansion in the spleens and lymph nodes of
DO11.10 adoptive transfer recipients. Significant clonal ex-
pansion (approximately fivefold) was induced by challenge
with pnir15.OVA-E. coli, but not the pnir15.TET-E. coli
control. The peak response measured was on day five, with
a rapid decline to baseline by day nine. Induction of a com-
parable peak response with free OVA required intraperito-
neal administration of a  100-fold higher dose of OVA
(100  g) in complete Freund’s or a block copolymer adju-
vant (data not shown), indicating that the bacterially associ-
ated OVA is more efficient at stimulating an in vivo
response. Collectively, these data indicate that the
pnir15.OVA plasmid produces high-level expression of
OVA that is potently immunogenic for DO11.10 T cells in
vitro and in vivo.
Rag-2 /  Mice Reconstituted with Th1- or Th2-polarized
DO11.RAG-2 /  T Cells Develop Severe Wasting Disease
that is Ova-E. coli–dependent; Mice Reconstituted with Antigen-
Naive DO11.10 T Cells Do Not Develop Wasting Disease.
To evaluate the in vivo responses of antigen-specific T
cells to a floral, bacterially associated antigen, OVA-spe-
cific T cells were transferred into congenic, immunodefi-
cient recipients whose intestinal tracts were colonized with
E. coli that expressed either OVA (pnir15.OVA-E. coli) or
a control antigen, TET (pnir15.TET-E. coli). Three T cell
populations were examined: naive CD4  T cells or Th1
and Th2 cells derived by short-term in vitro culture under
selective cytokine conditions. A 1 wk protocol was used
for Th1/Th2 derivation because it induced excellent po-
larization of cytokine phenotype (Fig. 3 A), but did not
significantly affect T cell migration to the secondary lym-
phoid organs compared with Th1 and Th2 cells main-
tained in vitro for longer periods of time (unpublished
data). In previous studies, we found that a fraction of
CD4  T cells that expressed the transgenic TCR in
DO11.10 mice coexpressed a second, endogenous TCR
that recognized bacterial antigens in the normal flora (35).
Figure 2. OVA-expressing E. coli induce clonal expansion of DO11.10
T cells in vivo. DO11.10/BALB/c adoptive transfer recipients were chal-
lenged with a single intravenous injection of 106 viable pnir15.OVA-E.
coli or pnir15.TET-E. coli. Two-color flow cytometric analysis was per-
formed on splenic or pooled peripheral lymph node lymphocytes isolated
at the indicated times after immunization as described in Materials and
Methods. The percentages of KJ1–26 CD4  cells in the lymphocyte gate
were determined and used to calculate the total number of splenic KJ1–26 
CD4  as described previously (reference 36). (A) Representative flow cy-
tometric profiles for lymph node lymphocytes isolated 5 d after challenge
with pnir15.TET-E. coli (left) or pnir15.OVA-E. coli (right). The percent-
ages of total gated cells in each quadrant are indicated. (B) Kinetics of
clonal expansion of total splenic KJ1–26 CD4  T cells induced by
pnir15.OVA-E. coli versus control pnir15.TET-E. coli. Data points are the
mean   SD of 3–4 animals per group.
Figure 3. Th1 and Th2 cells derived from DO11.RAG-2 /  mice
induce chronic wasting in RAG-2 /  recipients colonized with
pnir15.OVA-E. coli. (A) Cytokine analysis of naive and Th1- or Th2-
polarized OVA-specific T cells. Th1 and Th2 cells were generated in
vitro under polarizing cytokine conditions as described in Materials and
Methods. Briefly, CD4  T cells isolated from DO11.RAG-2 /  were
cultured for 7 d with OVA323–339 peptide, irradiated BALB/c spleno-
cytes, and either IL-12 plus anti–IL-4 (Th1) or IL-4 plus anti-IL-12
(Th2). To confirm Th1/Th2 polarization, aliquots were restimulated for
6 h with PMA and ionomycin, and analyzed for cytokine mRNA expres-
sion by ribonuclease protection assay (RPA; mCK-1 RiboQuant kit; BD
PharMingen) in comparison with naive T cell isolates. (B) Weight
changes of BALB.RAG-2 /  mice that were colonized with 1010 CFU
pnir15.OVA-E. coli (black symbols) or pnir15.TET-E. coli (white sym-
bols), reconstituted with 106 naive ( ), Th1 ( ), or Th2 ( ) cells from
DO11.RAG-2 /  donors and monitored for weight loss (B). Data are the
mean weekly weights and SD (n   5–6 mice per group).76 Both Th1 and Th2 Are Pathogenic in Colitis
Hence, the DO11.10 donors used for these experiments
were crossed onto a BALB.RAG-2 /  background
(DO11.RAG-2 / ) to obviate possible complications due
to dual TCR specificities. In preliminary colonization
studies, it was found that delivery of 1010 anaerobically in-
duced organisms by gastric gavage resulted in a transient
colonization of the colon (half-life of 3–4 d; data not
shown). Biweekly gavage maintained the floral colony
count at a minimum of 108 CFU per gram of colonic con-
tents and was used in experimental protocols.
1 d after gavage with anaerobically induced pnir15.
OVA-E. coli or pnir15.TET-E. coli, RAG-2 /  mice re-
ceived a transfer of 106 naive, Th1, or Th2 DO11.RAG-
2 /  CD4  T cells by tail vein injection. Bacterial coloni-
zation was maintained with biweekly gavage (1010 induced
organisms per dose), and mice were weighed and moni-
tored for clinical signs of disease (Fig. 3 B). Significant
weight loss was evident at week 6 in animals from groups
that were colonized with pnir15.OVA-E. coli and recon-
stituted with either Th1 or Th2 cell transfers. Mice that
received naive T cells and were colonized with pnir15.
OVA-E. coli did not show weight loss or clinical signs of
disease. Similarly, mice that received Th1 or Th2 cells and
were colonized with control pnir15.TET-E. coli also
showed no clinical evidence of disease. All mice were ad-
ministered 0.8 mg/ml BrdU in their drinking water for
9 d before sacrifice at week 8 and tissue was processed for
histological analyses.
At necropsy, macroscopic evaluation of animals from
Th1 and Th2 groups colonized with pnir15.OVA-E. coli
was remarkable for short, thickened large intestines. Focal
superficial erythema and hemorrhages were present on ce-
cal and colonic mucosal surfaces. The pnir15.TET-E. coli–
colonized Th1 and Th2 groups were grossly normal,
as were naive T cell recipients colonized with either
pnir15.OVA-E. coli or pnir15.TET-E. coli. On micro-
scopic evaluation, the large intestines from Th1 and Th2
groups colonized with pnir15.OVA-E. coli had moderate
to severe disease characterized by extensive inflammatory
cell infiltrates, marked epithelial cell hyperplasia and de-
pletion of epithelial cell mucin (Fig. 4). As shown in re-
sults from a representative experiment (Table I), the inci-
dence and severity of disease was comparable in Th1 and
Th2 groups. The distribution of involvement was also
similar in Th1- and Th2-mediated disease (Fig. 5), and
was patchy along the length of the cecum and colon. Dis-
ease severity was modestly increased in colon compared
with cecum; the rectum was spared. Although there was
good population of the small intestinal LP with clonotypic
T cells in all groups, no pathologic abnormalities were
identified (data not shown). Similarly, there was no in-
flammation in other organs
The histologic features of disease in Th1 and Th2 recipi-
ent mice colonized with pnir15.OVA-E. coli were distinct.
The lesions in mice that received Th1 cells were character-
ized by predominantly mononuclear cell infiltrates com-
posed of lymphocytes and monocytes/macrophages that
expanded the LP and distorted the crypt architecture (Fig.
Figure 4. Th1- and Th2-reconstituted mice colonized with
pnir15.OVA-E. coli develop antigen-specific colitis. H&E stained sections
of proximal colon from pnir15.OVA-E. coli–colonized recipients of naive
T cells (top), Th1 cells (middle), or Th2 cells (bottom) (original magnifi-
cation: 100 ).
Figure 5. Distribution of large intestinal disease mediated by Th1 and
Th2 cells. The large intestines of pnir15.OVA-E. coli-colonized RAG-2 / 
mice reconstituted with naive, Th1, or Th2 DO11.RAG-2 /  cells were
subdivided into the indicated anatomical regions and evaluated histologi-
cally for disease involvement as in Table I.77 Iqbal et al.
6 and Table II). Focally, there was extension of the inflam-
mation into the underlying muscularis and serosa. Scat-
tered, small granulomas were evident, but were not a dom-
inant feature. Frequent crypt abscesses were evident, and T
cells invaded the epithelium. Neutrophils were present in
the areas of most severe epithelial injury, particularly bor-
dering and infiltrating damaged crypts. Eosinophils were
rarely seen.
While the disease severity was comparable in pnir15.
OVA-E. coli-colonized Th2 animals, the histological fea-
tures were different (Fig. 6 and Table I). In contrast to
Th1-mediated disease, the inflammatory infiltrates in Th2
mice included a predominance of polymorphonuclear cells,
including a significant fraction of eosinophils ( 40% of to-
tal PMNs), with lesser numbers of lymphocytes and even
fewer monocytes/macrophages. The crypt architecture was
less tortuous, but crypts were markedly elongated and hy-
perplastic. Indeed, the mean crypt length in Th2 lesions
was generally greater than in Th1 lesions (Th2, 0.73 mm,
or 3.65 times nondiseased; Th1, 0.58 mm, or 2.64 times
nondiseased), consistent with a more hyperplastic epithelial
response in Th2 lesions. Compared with Th1-mediated
disease, there was less epithelial cell injury and necrosis, and
few crypt abscesses were found. There were significantly
fewer intraepithelial T cells in the Th2-diseased mucosa.
No granulomas were identified.
The distinct patterns of inflammation in diseased colons
of Th1- and Th2-reconstituted mice strongly suggested
that either effector T cell population could induce a patho-
genic response. However, given the short-term in vitro po-
larizations before transfer, and evidence for some heteroge-
neity of cytokine profiles of the starting T cell populations
(see RPA analysis, Fig. 3), it was possible that a shift in cy-
tokine phenotype might have occurred in vivo. To deter-
mine if the T cells present in colitic lesions retained a simi-
lar cytokine phenotype to those of the original T cell
populations transferred, cytokine analyses were performed
on recovered T cells (Fig. 7). CD4  T cells isolated from
the intestinal LP of pnir15.OVA-E. coli-colonized recipi-
ents reconstituted with Th1- or Th2-polarized DO11.
RAG-2 /  T cells were restimulated in vitro with plate-
bound anti-CD3 plus anti-CD28 and assayed for produc-
tion of IFN- , IL-4, and IL-10. Stimulated T cells from
the LP of Th1-reconstituted mice produced abundant
IFN-  and no detectable IL-4 or IL-10; LP T cells recov-
ered from Th2-reconstituted mice produced IL-4 and IL-10,
but no detectable IFN- . Thus, the distinct histopatholo-
gies were associated with strongly polarized Th1 or Th2
cells in the diseased intestinal tissues.
Interestingly, naive T cell recipients that were colonized
with pnir15.OVA-E. coli failed to develop clinical or histo-
logic evidence of disease (Table I and Figs. 2, 5, and 6).
BrdU incorporation studies indicated that this was not due
to absence of antigen recognition by naive DO11.RAG-
2 /  T cells (Fig. 6 and Table II). Thus, the frequency of
antigen-specific mucosal T cells that incorporated BrdU in
pnir15.OVA-E. coli-colonized mice reconstituted with na-
ive T cells was only modestly lower than that of Th1 or
Th2 mice, and was significantly increased compared with
controls that were colonized with pnir15.TET-E. coli. Sim-
ilarly, the density of T cells populating the colonic LP in
naive cell recipients colonized with pnir15.OVA-E. coli
was approximately fivefold greater than pnir15.TET-E. coli
controls (Table II). These results establish that naive
DO11.RAG-2 /  T cells populating pnir15.OVA-E. coli-
colonized mice were responsive to bacterially associated
OVA and underwent clonal expansion and/or recruitment
to the large intestinal tissues, but did not mediate disease
development. Thus, the absence of colitis in naive T cell
recipients was not due to a lack of antigenic responsiveness
(antigenic neglect) nor deficient trafficking of naive cells to
the colonic mucosa.
Bacterially Associated Antigen Is Required for Colitis Develop-
ment in Th1- and Th2-reconstituted RAG-2 /  Mice. Pre-
vious studies have shown that continuous oral delivery of
free OVA at a dose of 0.1  g/ml could activate DO11.10-
Table I. Histological Scoring of Colonic Pathology in DO11.RAG-2 /  /RAG-2 /  Recipients Colonized with E. coli-OVA versus
E. coli-TET 
T cells Intestinal colonization Colitisa Severity Hyperplasia Extent of involvement Total score
Naive pnir15.TET-E. coli 0/10 0.0   0.0b 0.0   0.0 0.0   0.0 0.0   0.0
pnir15.OVA-E. coli 1/10 0.1   0.3 0.1   0.3 0.1   0.3 0.3   1.0
Th1 pnir15.TET-E. coli 0/8 0.0   0.0 0.0   0.0 0.0   0.0 0.0   0.0
pnir15.OVA-E. coli 7/7 2.5   0.6 2.3   0.5 2.5   0.6 7.8   1.0
Th2 pnir15.TET-E. coli 0/7 0.0   0.0 0.0   0.0 0.0   0.0 0.0   0.0
pnir15.OVA-E. coli 6/6 2.3   0.6 2.7   0.5 2.3   0.3 7.3   0.6
RAG-2 /  recipients were reconstituted with 106 CD4+ T cells of the indicated phenotypes that were isolated or generated from DO11.RAG-2 / 
donors. 1 d before T cell reconstitution, recipients were colonized with 1010 CFU of the indicated bacteria and were maintained with biweekly
administration of an additional dose of 1010 CFU bacteria. 8 wk after reconstitution, mice were killed and necropsied.
aSee Materials and Methods for details of scoring system.
bAll data are the means   SEM of two independent pathological evaluations of the indicated numbers of mice pooled from three separate experi-
ments. Scores that differed significantly from control (P   0.05) are indicated in bold.78 Both Th1 and Th2 Are Pathogenic in Colitis
Figure 6. Histological analyses of colonic tissues
from mice with Th1- or Th2-mediated colitis. Par-
affin-embedded sections of colon from the indi-
cated experimental groups were processed and
stained as described in Materials and Methods. (A)
Th1- and Th2-reconstituted/pnir15.OVA-E. coli-
colonized, serial sections of proximal colon stained
with anti-CD3 to identify T cells (left, top, and
bottom) or Leder stain to identify neutrophils and
eosinophils (right, top, and bottom). Arrows iden-
tify intraepithelial Th1 cells in diseased proximal
colon. (B) Proximal colon from naive-reconstituted
RAG-2 /  mice colonized with pnir15.TET-E.
coli (top) or pnir15.OVA-E. coli mice (bottom)
stained with anti-CD3. (C) Low and high power
images of Th1-reconstituted/pnir15.OVA-E. coli–
colonized middle colon double-labeled with anti-
CD3 (brown) and anti-BrdU (red). Arrowheads
identify CD3  DO11.RAG-2 /  T cells that have
incorporated BrdU after 9 d in vivo administration.
Note also the incorporation of BrdU by colonic
crypt epithelial cells.79 Iqbal et al.
derived Tr1 regulatory cells to control colitis development
in adoptively transferred mice (47). We sought to deter-
mine if free OVA delivered to RAG-2 /  mice reconsti-
tuted with DO11.RAG-2 /  Th1 and Th2 cells would be
sufficient to cause intestinal disease, or whether bacterially
associated OVA was required. RAG-2 /  mice were re-
constituted with DO11.RAG-2 /  Th1 and Th2 cells and
were challenged with free versus bacterially associated
OVA. Free OVA was delivered continuously in the
drinking water over an 8-wk course, with or without
pnir15.TET-E. coli colonization to control for potential
nonspecific adjuvanticity of the E. coli organisms used for
colonization (Fig. 8). Control animals received no OVA or
pnir15.OVA-E. coli.
In contrast to Th1 and Th2 recipients colonized with
pnir15.OVA-E. coli, animals challenged with free OVA did
not develop significant disease, irrespective of whether they
were also colonized with pnir15.TET-E. coli control or-
ganisms (Fig. 8). To determine if this was due to an absence
of antigenic exposure of colonic T cells in animals fed
OVA, the recruitment and/or proliferation of T cells in the
colonic LP were assessed. Th1 recipients challenged with
low dose OVA (0.1  g/ml) did not have appreciably in-
creased densities of T cells in the LP compared with no an-
tigen controls (92.5 vs. 78.0 CD3  cells/mm2), but a
significantly greater fraction of T cells present had
incorporated BrdU (4.2 vs. 0.8%). At the higher dose of
free OVA (1,000  g/ml), both the T cell density and fre-
quency of BrdU-labeled cells were increased compared
with no antigen controls, albeit less so than in animals colo-
nized with pnir15.OVA-E. coli. Interestingly, Th2-recon-
stituted mice treated with both low and high doses of free
OVA had increases in T cell densities in the colonic LP that
were comparable to pnir15.OVA-E. coli–colonized con-
trols. However, although frequencies of BrdU-positive
cells were greater than the no antigen controls in both
groups treated with free OVA, the frequencies were signif-
icantly lower than in the pnir15.OVA-E. coli-colonized
group. This suggests that there might be more rapid turn-
over of colonic T cells stimulated with bacterially associ-
ated OVA than free OVA. Nevertheless, the absence of
colitis in Th1 and Th2 recipient mice challenged with free
OVA was not due to the absence of antigen recognition by
Table II. Histological Characterization of Inflammatory Lesions in DO11.RAG-2 / /RAG-2 /  Recipients Colonized with E. coli-OVA 
versus E. coli-TET 
T cells Intestinal colonization
CD3 /mm2
totala
CD3 /mm2
IEL
PMN/mm2
total
Percentage of eosinophils
(PMNs)
Percentage of BrdU 
(CD3)
Naive pnir15.TET-E. coli 77.4   44.2b 5.5   5.0 4.0   3.7 ND 1.6   1.7
pnir15.OVA-E. coli 192.3   73.5 7.3   3.6 8.5   3.8 2.4   2.9 24.0   5.2
Th1 pnir15.TET-E. coli 203.7   55.8 17.9   8.4 17.9   8.4 ND 2.5   1.8
pnir15.OVA-E. coli 796.1   190.3 66.5   29.3 246.0   97.3 5.7   4.8 34.8   7.6
Th1 pnir15.TET-E. coli 140.1   50.0 13.0   8.3 0.5   1.0 ND 7.5   1.9
pnir15.OVA-E. coli 385   96.2 33.0   5.2 496.7   44.7 39.6   8.9 38.8   9.6
RAG-2 /  recipients were reconstituted with 106 CD4+ T cells of the indicated phenotypes that were isolated/generated from DO11.RAG-2 / 
donors. 1 d before T cell reconstitution, recipients were colonized with 1010 CFU of the indicated bacteria and maintained with biweekly
administration of an additional dose of 1010 CFU bacteria. 8 wk after reconstitution, mice were killed and necropsied.
aThe total number of CD3+ T cells per mm2 of colonic mucosa, including LP and IEL compartments (see Material and Methods for details).
bData are the means ± SEM from 3–6 animals per group. Values that differed significantly from control (P   0.05) are indicated in bold font.
ND, not determined.
Figure 7. T cells recovered from colitic mice retain a polarized Th1 or
Th2 phenotype. Intestinal tissues from Th1 and Th2 adoptive transfer re-
cipients colonized with pnir15.OVA-E. coli were recovered and processed
for isolation of LP lymphocytes 8 wk after transfer (Materials and Meth-
ods). CD4  T cells were purified by magnetic sorting and stimulated with
plate-bound anti-CD3 and anti-CD28 for 72 h. Culture supernatants
were assayed for IFN- , IL-4, and IL-10 by ELISA. Data are the means
and SD of triplicate determinations for T cells pooled from 6–10 mice per
group. The detection limits of the respective ELISA assays are indicated
for those values that were not greater than background (P   0.01).80 Both Th1 and Th2 Are Pathogenic in Colitis
the DO11.RAG-2 /  T cells, and was not due to lack of
an independent adjuvant effect of the E. coli bacterial host.
These data indicate that stimulation by bacterially associ-
ated antigen is both necessary and sufficient for the devel-
opment of colitis in this model.
Discussion
This paper establishes that a single bacterially associated
antigen is both necessary and sufficient to cause colitis me-
diated by a defined, monoclonal T cell population. In this
model, transfer of both Th1 and Th2 cells derived from
OVA-specific DO11.RAG-2 /  donors was associated
with colitis that was dependent on the colonization of
RAG-2 /  recipient mice with E. coli that expressed OVA.
Importantly, transfer of antigen-naive T cells of identical
specificity did not induce appreciable disease, despite in
vivo responsiveness to bacterially associated antigen. Fur-
ther, in vivo recognition of free antigen by either Th1 or
Th2 effectors was insufficient to induce colitis. Taken to-
gether, these results suggest that both committed effector T
cells and bacterially associated antigen are required for dis-
ease pathogenesis in this model, and emphasize the fact that
unopposed Th1 and Th2 responses to enteric bacterial anti-
gens can be equally deleterious to the host.
In each of the rodent models of colitis studied to date,
disease development has been associated with the presence
of the enteric flora. However, in none of these models has
the relevant bacterial antigens been identified, and it has
been difficult to define contributions from distinct bacterial
species or specific antigens. The lack of identification of ei-
ther the antigenic targets or T cell specificities responsible
for disease has compromised efforts to understand the
pathogenic contribution of the enteric flora. Studies of
spontaneously colitic C3H/HeJBir mice have demon-
strated a surprisingly selective immune reactivity to the en-
teric flora, and have suggested that facultative anaerobes
such as E. coli and Salmonella species were immune stimula-
tory organisms, despite comprising  1% of the total bacte-
rial flora (28). Similarly, Bacteroides spp. was a common
component of bacterial cocktails that induced colitis in
germ-free HLA-B27 transgenic rats colonized with defined
flora (22). Helicobacter hepaticus has been proposed as a req-
uisite component of the enteric flora in the CD45RB
transfer and IL-10 /  colitis models (48, 49), although this
has been controversial (50). However, the diversity and
specificities of the T cell populations responsive to these
bacteria are yet to be defined in these or other IBD models.
Advantages of the DO11.10 OVA colitis model described
here include the ability to track a specific T cell population
that is responsive to a defined bacterially associated antigen
in vivo (45, 46), and the ability to control the developmen-
tal stage and effector function of the T cell population. This
model also offers the potential to vary the bacterial host and
the bacterial compartment in which the target antigen,
OVA, is expressed.
A technical impediment confronted at the outset of these
studies was difficulty in the development of bacterial strains
that could stably express OVA in vivo and could establish
colonization of a murine host. Poor retention of plasmids
and/or silencing of plasmid promoters have hampered ef-
forts to express heterologous antigens in bacterial vectors in
vivo (31). It has also been difficult to establish long-term
colonization of laboratory strains of bacteria introduced
into the normal flora (33). Adoption of the pnir15 pro-
moter has extended expression of OVA in vivo, and we
have been able to document stable plasmid retention and
expression of OVA up to 5 wk after a single inoculation of
pnir15.OVA-E. coli (data not shown). We have had less
success maintaining long-term colonization by the DH5 
E. coli strain used in these studies without repeated bacterial
inoculation. More recent efforts using E. coli strains derived
Figure 8. DO11.RAG-2 / /RAG-2 /  recipients fed OVA do not
develop colitis. RAG-2 /  recipients were reconstituted with 106 CD4 
Th1 or Th2 cells generated from DO11.RAG-2 /  donors. 1 d before T
cell reconstitution, recipients were colonized with 1010 CFU of the indi-
cated bacteria, and maintained with biweekly administration of an addi-
tional dose of 1010 CFU bacteria. 8 wk after reconstitution, mice were
killed and necropsied. Colonic and cecal disease was scored as described
in Materials and Methods; mean total scores and SEM are indicated (bot-
tom). BrdU (0.8 mg/ml) was added to the drinking water of indicated
groups for 9 d before sacrifice; intestinal tissues were processed and evalu-
ated as in Table II for CD3  cell densities (middle) and BrdU incorpora-
tion (top). Data are from two experiments and are the means   SEM
from 4–8 animals per group. Values that differed significantly from con-
trol (P   0.05) are indicated with an asterisk. ND, not done.81 Iqbal et al.
from the normal flora of mice in our colony have resulted
in prolonged colonization (unpublished data) and are being
characterized for future studies. Nevertheless, it is clear
from our results that the protocol developed for in vivo de-
livery of bacterially associated OVA is effective.
This study establishes that a single antigenic specificity
can drive the development of colitis by both Th1 and Th2
effectors, but does not prove that specific bacterial antigens
are responsible for pathogenic T cell responses in other
colitis models or in human disease. Indeed, pioneering
studies by Braun et al. has identified by representational dif-
ference analysis a novel bacterial superantigen, I2, which is
associated with inflammatory lesions in patients with
Crohn’s disease (51). While a causal relationship between
this molecule and Crohn’s disease is not yet established, this
study raises the possibility that bacterial superantigens rather
than specific bacterial antigens are important contributors
to a pathogenic T cell response. However, TCR repertoire
analyses in monozygotic twins with Crohn’s disease do not
support a major role for superantigens (52). Further, recent
studies of the TCR-  repertoire of T cells from colitic ani-
mals in the CD45RB and C3H/HeJBir colitis models favor
an oligoclonal T cell response to specific bacterial antigens
rather than a superantigen (27, 53, 54). In the present
model, colonization of adoptive transfer recipients with E.
coli that express a control antigen (TET) did not develop
disease, and there was no evidence of reactivity of either
naive or effector DO11.10 T cells to control E. coli or the
endogenous enteric flora of RAG-2 /  hosts. Hence, this
model does not involve a contribution by bacterial super-
antigens, and demonstrates that superantigens are not re-
quired for colitis development.
The induction of colitis by both Th1 and Th2 effector
cells in this model was somewhat unanticipated. Although
elevated Th2 cytokines have been demonstrated in the
TCR-  /  and oxazalone colitis models (15, 16), the ma-
jority of the rodent models that have been described dem-
onstrate characteristics of a Th1-mediated disease. In the
well-characterized CD45RB colitis model, CD4 T cells re-
covered from animals with active disease produced Th1 cy-
tokines and disease was attenuated by in vivo neutralization
of IL-12, IFN- , and TNF-  (11, 13). The colitis that de-
velops in IL-10 /  mice also has a Th1 cytokine profile
(14). Not surprisingly, the Th1-mediated disease in our
model had histopathologic features that closely resembled
those of both CD45RB and IL-10 /  models with respect
to the pattern of inflammation, extent, and distribution of
intestinal involvement and disease severity. In each of these
models, the inflammatory lesions are distributed through-
out the cecum and colon and are characterized by focally
dense infiltrates of CD4 T cells and monocytes, with lesser
numbers of neutrophils.
Unexpectedly, the colitic lesions induced by Th2 trans-
fers in the current model were of comparable severity to
those mediated by Th1 cell transfers, albeit with distinct
histopathologic features. The composition of inflammatory
lesions in Th2 colitis was characterized by lesser numbers
of infiltrating T cells accompanied by numerous neutro-
phils and eosinophils. Interestingly, the acute inflammatory
infiltrates (neutrophils and eosinophils) were more promi-
nent in Th2-mediated disease despite a paucity of epithelial
necrosis compared with that seen in Th1-mediated lesions.
This finding is consistent with the enhanced recruitment of
these cells by cytokines and chemokines produced by acti-
vated Th2 cells. The Th2-mediated lesions also demon-
strated a more striking hyperplasia of the crypt epithelium
than in Th1 lesions, although epithelial hyperplasia was a
prominent feature of both diseases. Although we have not
directly compared the histology in our Th2 model with
that of the TCR-  /  or oxazalone models, the patho-
logic features most closely resemble the published charac-
terizations of the former (55). Given the association of dis-
ease in both of these models with IL-4, it will be important
to determine if IL-4 plays a pathogenic role in the current
model. In any case, the pathogenic potential of an unop-
posed Th2 response in this model strikes a cautionary note
with respect to therapeutic strategies aimed at reversing
Th1-mediated autoinflammatory disease by augmenting
Th2 activity. In this regard, it has been shown that IL-4
treatment can exacerbate Th1 type colonic inflammation
in the CD45RBhi adoptive transfer model (56). This is in
agreement with studies that have demonstrated a patho-
genic rather than protective role for Th2 cells in murine
models of multiple sclerosis (experimental allergic enceph-
alitis) and diabetes (NOD mice) (57, 58). Similarly, in re-
cent murine models of asthma also based on adoptive
transfers of DO11.10 T cells, both Th1 and Th2 cells were
pathogenic, and cotransfers of both cell types exacerbated
rather than controlled disease (59, 60). Thus, although the
nature of the chronic inflammatory lesions induced by
chronic Th1 and Th2 activation is different, unopposed
responses of either can be pathogenic to the intestinal and
extraintestinal tissues.
A curious feature of the current model concerns the
tempo of disease development mediated by Th1 and Th2
transfers into OVA-E. coli–colonized mice. Similar to each
of the spontaneous colitis models that have been character-
ized, development of clinically apparent disease after Th1
or Th2 transfers evolved over a period of several weeks to
months. In previous models, where the precursor fre-
quency of pathogenic or protective T cells was not defined,
it was plausible that this relatively slow development of dis-
ease was due to a requirement for clonal expansion of a
pathogenic T cell population that was initially limiting in
the repertoire. Given the monoclonality of the pathogenic
T cells in the current model, it is surprising that disease de-
velopment is not accelerated relative to other models. It is
also provocative that Th1 and Th2 disease development
progressed at similar rates. This suggests that the rate-limit-
ing step for disease induction and progression in this model
may not be the availability of pathogenic T cells. Rather,
the immunogenicity of the relevant bacteria or the rate at
which translocations of the relevant enteric bacteria occur
might be more critical. Because the OVA-E. coli used in
this study are quite potently immunogenic (Figs. 1 and 2),
we favor a dominant role for the latter. The rate of bacte-82 Both Th1 and Th2 Are Pathogenic in Colitis
rial translocation is typically low for commensal organisms,
and is related to the density of a given bacterial species in
the enteric flora and its representation relative to other bac-
terial species that comprise the flora (61). In our studies, re-
duced colonization by OVA-E. coli to levels below  107
CFU/g of lumenal contents resulted in a marked decrease
in disease severity and incidence despite transfers of the
same number of Th1 or Th2 cells (data not shown). This
suggests that the rate at which bacteria are transported
across the mucosa may be limiting, and might explain the
focal nature of lesions in this and other colitis models, as
well as the relatively slow progression of disease. Since the
specific bacterial species responsible for disease is identified
in the DO11.10/OVA-E. coli model, it will be possible to
examine this directly. It would be predicted that higher
colonization rates or delivery of OVA via more invasive
organisms would accelerate disease development, and stud-
ies to directly quantitate this are in progress.
The basis for the lack of colitis development in recipients
of antigen-naive DO11.RAG-2 /  T cells colonized with
OVA-E. coli is not yet known, but it is not due to antigenic
ignorance or neglect, nor defective trafficking of reactive T
cells to the colonic mucosa. Since in previous models of
colitis the differentiation state of the T cell population at
the onset of experimental protocols could not be defined, it
has been unclear whether a pathogenic population was pre-
existent in the T cell repertoire or developed in response to
stimulation by enteric bacteria. In the CD45RB colitis
model, for example, it has not been possible to determine
whether the pathogenic Th1 response has been due to the
development of a Th1 effector population from un-
committed CD45RBhigh precursors in the absence of
CD45RBlow regulatory cells, or whether it was due to the
release of committed, memory CD45RBhigh Th1 cells from
regulatory control (20). Our data are inconsistent with the
former mechanism, since recipients of a uniformly naive
(and CD45RBhigh) population of T cells did not develop
colitis, despite the absence of a CD45RBlow regulatory
population. This suggests that a committed Th1 or Th2
population may be required for disease development and/
or may recruit the differentiation of naive precursors acti-
vated by bacterial antigens. Alternatively, naive CD4 T
cells responsive to bacterially associated antigen in the ab-
sence of either pathogenic or regulatory effector cell popu-
lations may reestablish a homeostatic balance of both
pathogenic and regulatory T cells. Experiments to distin-
guish these alternatives can be addressed in our model, and
are in progress.
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